ANTIGENeering
Genetic Immunity's disease specific Antigen Selection and Construction (ANTIGENeering) technology employs state of art molecular biology to express
most of the disesase specific antigens as immunogens from a single plasmid DNA.
Main features of Genetic Immunity's ANTIGENeering technology include:
- single plasmid DNA to encode most of the disease specific antigens
- regulation and optimization of different disease specific antigen expression to mimic the authentic antigen-presenting profile
- safety is ensured by molecular specific modifications of the plasmid DNA
- validated QC of antigen identity, quality, quantity and potency
- cost-effective, reproducible, scalable manufacturing process
- plasmid DNA can be formulated to pathogen-like, intelligent nanoparticles - Nanomedicine
- dendritic cell targeting administration with DermaPrep topical delivery device
Case Study: ANTIGENeering of plasmid DNA for safe expression of HIV antigens
The Active Pharmaceutical Ingredient (API) in our lead product candidate - DermaVir Patch - is a single plasmid-DNA designed to
authentically express most HIV antigens. A summary of our ANTIGENeering modifications are:
| General features of ANTIGENeering | Specific features of DermaVir's pDNA |
|
| HIV-specific antigen expression | Gag, Protease, Reverse transcriptase, Env, Tat, Rev, Vif, Vpr |
|
| Virus-like particle release | Yes |
|
| Safety features | Integrase defective
Reverse transcription impaired
Nef truncated |
|
| Regulation of gene expression | HIV-1 LTR promoter |
|
| Testing | Sequencing, restriction digestion, physical and chemical characteristic, potency in human cells |
Subtype-B HIV is the prevalent type in the USA, Europe, Australia and parts of Asia. Genetic Immunity's plasmid DNA, as utilized in the
DermaVir Patch, encodes 90% of subtype-B HIV antigens. In addition to subtype-B, ANTIGENeering supports rapid development of DermaVir Patch
varieties for personalized subtype-specific treatment. By replacing the plasmid DNA in DermaVir B with other subtype-optimized plasmid DNA other
variants of DermaVir can be made that are suitable for inducing subtype-optimized immune responses.
In addition to our subtype-B HIV vaccine we are also actively engaged in developing plasmid DNA immunogens for the following subtypes:
| DermaVir | Targeted epidemics | Infected population |
|
| Subtype C | Sub-Saharan Africa, South-Asia | 22.5 million |
| Subtype B/C | China | 3.3 million |
| Subtype B/F | South-America | 1.6 million |
| Subtype A | East- & West-Africa, Middle-East | 2.0 million |
| Subtype A/B | East-Europe | 10,000 |
In order to manufacture different DermaVir Therapeutic Vaccines the subtype-optimized plasmid DNA is nanoformulated to pathogen-like
intelligent nanoparticles (Nanomedicine) to improve its stability and immunogenicity. DermaVir is topically administered using DermaPrep
to target lymph node dendritic cells.
| |
|
